In this free webinar, see how DPYD testing can be implemented from guidelines to go-live through practical pharmacogenomics (PGx) reporting and workflow design. The featured speakers will share ...

HOUSTON, Oct. 16, 2025 /PRNewswire/ -- Oncologists and pharmacy experts are reacting to last week's Food and Drug Administration warning that requires genetic testing on patients receiving the common ...

5-Fluorouracil (5-FU) and capecitabine are fluoropyrimidine chemotherapies that are used to treat a range of solid tumours including breast, pancreatic, stomach and colorectal. Metabolism of ...

IRVING, Texas, March 24, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric, next-generation AI TechBio company and precision medicine pioneer, is recognizing ...

Genomic medicine leverages an individual’s genetic information to guide healthcare decisions, with drug-gene testing (also known as pharmacogenomics, or PGx) being a key application that personalizes ...

National clinical guidelines don’t mention screening cancer patients for DPYD gene variants, but hospital pharmacy leaders are forging ahead with the patient safety practice, the American Society of ...

5-fluorouracil (5-FU) and its oral analog capecitabine are fluoropyrimidine chemotherapy agents used in several solid tumors. Approximately 5% of patients inherit diminished or null activity genetic ...

A man in his early 70s died after adjuvant chemotherapy due to fulminant gastrointestinal toxicity and bowel ischaemia linked to an undetected dihydropyrimidine dehydrogenase (DPYD) deficiency, ...

Aranscia® solutions help oncologists comply with new FDA warning label requiring DPYD genetic testing in patients receiving select chemotherapies HOUSTON, Oct. 16, 2025 /PRNewswire/ -- Oncologists and ...